Mxi1 belongs to the Mad (Mxi1) family of proteins, which function as p
otent antagonists of Myc oncoproteins(1-4). This antagonism relates pa
rtly to their ability to compete with Myc for the protein Max and for
consensus DNA binding sites and to recruit transcriptional co-represso
rs(4-6). Mad(Mxi1) proteins have been suggested to be essential in cel
lular growth control and/or in the induction and maintenance of the di
fferentiated state(6-7) Consistent with these roles, mxi1 may be the t
umour-suppressor gene that resides at region 24-26 of the long arm of
chromosome 10. This region is a cancer hotspot, and mutations here may
be involved in several cancers, including prostate adenocarcinoma(8-1
0). Here we show that mice lacking Mxi1 exhibit progressive, multisyst
em abnormalities. These mice also show increased susceptibility to tum
origenesis either following carcinogen treatment or when also deficien
t in Ink4a. This cancer-prone phenotype may correlate with the enhance
d ability of several mxi1-deficient cell types, including prostatic ep
ithelium, to proliferate. Our results show that Mxi1 is involved in th
e homeostasis of differentiated organ systems, acts as a tumour suppre
ssor in vivo and engages the Myc network in functionally relevant mann
er.